Insider Selling: ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Sells 400 Shares of Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $61.37, for a total value of $24,548.00. Following the completion of the sale, the vice president now directly owns 79,345 shares in the company, valued at approximately $4,869,402.65. This represents a 0.50% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Meredith Cook also recently made the following trade(s):

• On Monday, April 14th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $68.96, for a total transaction of $27,584.00.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP traded up $1.73 during midday trading on Monday, hitting $64.29. 323,229 shares of the company's stock were exchanged, compared to its average volume of 310,670. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The firm has a market capitalization of $1.39 billion, a PE ratio of -116.89 and a beta of 0.55. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $77.00. The company's 50 day moving average price is $64.74 and its 200 day moving average price is $61.10.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, May 9th. The specialty pharmaceutical company reported $1.70 EPS for the quarter, topping analysts' consensus estimates of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same period in the previous year, the business posted $0.82 earnings per share. The company's revenue for the quarter was up 43.4% compared to the same quarter last year. As a group, analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC lifted its position in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company's stock worth $55,437,000 after acquiring an additional 473,097 shares during the last quarter. Aberdeen Group plc increased its stake in shares of ANI Pharmaceuticals by 76.1% during the first quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company's stock worth $28,059,000 after purchasing an additional 181,134 shares during the period. Woodline Partners LP acquired a new stake in ANI Pharmaceuticals during the 1st quarter worth approximately $11,144,000. Deep Track Capital LP boosted its stake in ANI Pharmaceuticals by 28.6% in the 4th quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company's stock valued at $35,879,000 after purchasing an additional 144,214 shares during the period. Finally, Global Alpha Capital Management Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 17.8% during the first quarter. Global Alpha Capital Management Ltd. now owns 735,590 shares of the specialty pharmaceutical company's stock worth $49,248,000 after buying an additional 111,040 shares in the last quarter. Institutional investors and hedge funds own 76.05% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on ANIP shares. Wall Street Zen cut shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. JPMorgan Chase & Co. initiated coverage on ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Finally, Guggenheim reissued a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $80.13.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.